Skip to Content

Imprida

Active Substance: amlodipine (as besylate) / valsartan
Common Name: amlodipine / valsartan
ATC Code: C09DB01
Marketing Authorisation Holder: Novartis Europharm Ltd
Active Substance: amlodipine (as besylate) / valsartan
Status: Withdrawn
Authorisation Date: 2007-01-17
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system

Therapeutic Indication

Treatment of essential hypertension.

Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

The marketing authorisation for Imprida has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide